Sugi Predict

Sugi Predict / Compounds / SCHEMBL64588

SCHEMBL64588

SCHEMBL64588

COC(=O)c1ccc(CN2CCN(C)CC2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHKA P35790 2/20 0.82
▸ HDAC6 Q9UBN7 2/20 0.68
▸ KDM4E B2RXH2 1/20 0.60
▸ MAPT P10636 2/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ GAA P10253 2/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ HPGD P15428 1/20 0.60
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ HRH3 Q9Y5N1 2/20 0.57
▸ LMNA P02545 2/20 0.56
▸ BTK Q06187 1/20 0.54
▸ HDAC3 O15379 1/20 0.54
▸ HDAC4 P56524 1/20 0.54
▸ HDAC1 Q13547 1/20 0.54
▸ HDAC7 Q8WUI4 1/20 0.54
▸ HDAC2 Q92769 1/20 0.54
▸ HDAC10 Q969S8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4367804 1.00 CHKA (0.82) CHKAHDAC6KDM4EMAPTALDH1A1
SCHEMBL16121573 0.91 CHKA (1.00) CHKAHDAC6KDM4EMAPTGAA
SCHEMBL10899174 0.88 MAPT (0.74) CHKAKDM4EMAPTALDH1A1GAA
SCHEMBL19609177 0.88 CHKA (0.65) CHKAHDAC6KDM4EMAPTALDH1A1
SCHEMBL17078457 0.87 CHKA (0.65) CHKAHDAC6KDM4EMAPTALDH1A1
SCHEMBL2873979 0.87 CHKA (0.72) CHKAHDAC6KDM4EMAPTALDH1A1
SCHEMBL20210248 0.87 CHKA (0.77) CHKAHDAC6KDM4EMAPTALDH1A1
SCHEMBL24892467 0.87 CHKA (0.64) CHKAHDAC6KDM4EMAPTALDH1A1
SCHEMBL25509878 0.86 CHKA (0.64) CHKAHDAC6KDM4EMAPTALDH1A1
SCHEMBL10901528 0.86 CHKA (0.64) CHKAHDAC6KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140121215-A1 PROCESS FOR THE PREPARATION OF AMORPHOUS IMATINIB MESYLATE CADILA HEALTHCARE LIMITED (IN) 2014-05-01 — — US claimed
US-20250092032-A1 DEOXYCYTIDINE KINASE INHIBITORS INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER (FR) 2025-03-20 — — US disclosed
WO-2023135330-A1 DEOXYCYTIDINE KINASE INHIBITORS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-07-20 — — WO disclosed
WO-2023287793-A1 THERAPEUTIC COMPOUNDS AND METHODS GENENTECH, INC. (US) 2023-01-19 — — WO disclosed
CN-112500353-B Levosimendan prodrug compound, preparation method and application thereof 北京晨光同创医药研究院有限公司 2022-11-25 — — CN disclosed
CN-112500353-A Levosimendan prodrug compound, preparation method and application thereof 北京晨光同创医药研究院有限公司 2021-03-16 — — CN disclosed
US-10301267-B2 Compounds ASTRAZENECA AB (SE) 2019-05-28 — — US disclosed
US-9949968-B2 Diarylalkylamine REV-ERB antagonists and their use as medicaments FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2018-04-24 — — US disclosed
US-9949968-B2 Diarylalkylamine REV-ERB antagonists and their use as medicaments FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2018-04-24 — — US disclosed
US-9949968-B2 Diarylalkylamine REV-ERB antagonists and their use as medicaments FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2018-04-24 — — US disclosed
WO-2004096225-A2 USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA AB SCIENCE (FR) 2004-11-11 — — WO disclosed
EP-1474408-A1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES Novartis AG (CH) 2004-11-10 — — EP disclosed
US-20040180914-A1 5-Cyano-2-aminopyrimidine derivatives CELLTECH R&D LIMTIED 2004-09-16 — — US disclosed
WO-2004063191-A1 PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM ORION CORPORATION (FI) 2004-07-29 — — WO disclosed
WO-2004014903-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2004-02-19 — — WO disclosed
WO-2003066613-A1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES NOVARTIS AG (CH) 2003-08-14 — — WO disclosed
US-6579983-B1 Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase CELLTECH R&D LIMITED (GB) 2003-06-17 — — US disclosed
US-20020147339-A1 5-cyano-2-aminopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2002-10-10 — — US disclosed
EP-1187816-A1 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES Celltech R&D Limited (GB) 2002-03-20 — — EP disclosed
WO-2000078731-A1 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES CELLTECH R&D LIMITED (GB) 2000-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140121215-A1 PROCESS FOR THE PREPARATION OF AMORPHOUS IMATINIB MESYLATE ABL1, ABL2, ALK CHKA 3907/4885HDAC6 1206/4885KDM4E 793/4885
US-10301267-B2 Compounds SLC10A1, CYP11B1, ABCB11 CHKA 2898/4885HDAC6 167/4885KDM4E 2865/4885
US-20040180914-A1 5-Cyano-2-aminopyrimidine derivatives FLT1, FGFR1, KDR CHKA 1453/4885HDAC6 2258/4885KDM4E 2547/4885
US-20250092032-A1 DEOXYCYTIDINE KINASE INHIBITORS DCK, DTYMK, TYMP CHKA 137/4885HDAC6 1678/4885KDM4E 689/4885
US-20020147339-A1 5-cyano-2-aminopyrimidine derivatives FLT1, FGFR1, KDR CHKA 1527/4885HDAC6 2314/4885KDM4E 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.